A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases

Blood Cancer Journal

Volumn 3, Issue 11, 2013, Pages

  Hayakawa, F ^a   Sugimoto, K ^a,b   Harada, Y ^b   Hashimoto, N ^b   Ohi, N ^b   Kurahashi, S ^a   Naoe, T ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Novel STAT inhibitor; OPB 31121

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; FLT3 LIGAND; JANUS KINASE 2; OPB 31121; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER CELL; CANCER GROWTH; CARCINOGENICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME INHIBITION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IC 50; LEUKEMIA; LEUKEMIA CELL LINE; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PROTEIN PHOSPHORYLATION; UMBILICAL CORD BLOOD;

EID: 84888424589     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.63     Document Type: Article

References (39)

1. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996; 84: 331-334. (Pubitemid 26058558)
2. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293-322. (Pubitemid 28183367)
3. Hayakawa F, Naoe T. SFK-STAT pathway: an alternative and important way to malignancies. Ann NY Acad Sci 2006; 1086: 213-222. (Pubitemid 47084370)
4. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Kuriyan Jr J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998; 93: 827-839. (Pubitemid 28257588)
5. Shuai K, Horvath CM, Huang LH, Qureshi SA, Cowburn D, Darnell Jr JE. Interferon activation of the transcription factor Stat91 involves dimerization through SH2- phosphotyrosyl peptide interactions. Cell 1994; 76: 821-828. (Pubitemid 24085320)
6. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553-2558. (Pubitemid 28183425)
7. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998; 18: 2545-2552. (Pubitemid 28183424)
8. Besser D, Bromberg JF, Darnell Jr JE, Hanafusa H. A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol Cell Biol 1999; 19: 1401-1409. (Pubitemid 29046881)
9. Zong CS, Zeng L, Jiang Y, Sadowski HB, Wang LH. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorageindependent growth. J Biol Chem 1998; 273: 28065-28072. (Pubitemid 28496100)
10. Migone TS, Lin JX, Cereseto A, Mulloy JC, O'Shea JJ, Franchini G et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 1995; 269: 79-81.
11. Weber-Nordt RM, Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996; 88: 809-816. (Pubitemid 26333300)
12. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science 1995; 269: 1875-1877.
13. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene 2000; 19: 2523-2531. (Pubitemid 30339208)
14. de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 1999; 94: 1108-1112. (Pubitemid 29361844)
15. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J Exp Med 1999; 189: 1229-1242. (Pubitemid 29198261)
16. Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000; 95: 2118-2125. (Pubitemid 30151654)
17. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000; 19: 624-631. (Pubitemid 30102913)
18. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907-3914.
19. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci USA 2005; 102: 18962-18967. (Pubitemid 43049549)
20. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C et al. Stat3 as an oncogene. Cell 1999; 98: 295-303. (Pubitemid 29380565)
21. Onishi M, Nosaka T, Misawa K, Mui AL, Gorman D, McMahon M et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol 1998; 18: 3871-3879. (Pubitemid 28287910)
22. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Exp Opin Invest Drug 2009; 18: 45-56.
23. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012; 489: 155-159.
24. Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009; 114: 1607-1617.
25. Kim MJ, Nam HJ, Kim HP, Han SW, Im SA, Kim TY et al. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 2013; 335: 145-152.
26. Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S et al. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene 2011; 30: 1822-1830.
27. Tanizaki R, Nomura Y, Miyata Y, Minami Y, Abe A, Hanamura A et al. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL- 2Rgammac-/- mice. Cancer Sci 2010; 101: 631-638.
28. Okamoto M, Hayakawa F, Miyata Y, Watamoto K, Emi N, Abe A et al. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 2007; 21: 403-410.
29. Oh D, Han S, Kim TM, Lee S, Kim T, Heo DS et al. A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2010; 28: e13056.
30. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
31. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811-820. (Pubitemid 26113953)
32. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 2009; 113: 4052-4062.
33. Page BD, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Exp Opin Ther Patent 2011; 21: 65-83.
34. Lai SY, Johnson FM. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Update Rev Comment Antimicrob Anticancer Chemother 2010; 13: 67-78.
35. Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011; 71: 3182-3188.
36. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079. (Pubitemid 30616875)
37. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690-698. (Pubitemid 36077594)
38. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169-3175.
39. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116: 5089-5102.